Literature DB >> 22593150

Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.

Brittney L Gurda1, Christina Raupp, Ruth Popa-Wagner, Matthias Naumer, Norman H Olson, Robert Ng, Robert McKenna, Timothy S Baker, Jürgen A Kleinschmidt, Mavis Agbandje-McKenna.   

Abstract

Adeno-associated viruses (AAVs) are small single-stranded DNA viruses that can package and deliver nongenomic DNA for therapeutic gene delivery. AAV8, a liver-tropic vector, has shown great promise for the treatment of hemophilia A and B. However, as with other AAV vectors, host anti-capsid immune responses are a deterrent to therapeutic success. To characterize the antigenic structure of this vector, cryo-electron microscopy and image reconstruction (cryo-reconstruction) combined with molecular genetics, biochemistry, and in vivo approaches were used to define an antigenic epitope on the AAV8 capsid surface for a neutralizing monoclonal antibody, ADK8. Docking of the crystal structures of AAV8 and a generic Fab into the cryo-reconstruction for the AAV8-ADK8 complex identified a footprint on the prominent protrusions that flank the 3-fold axes of the icosahedrally symmetric capsid. Mutagenesis and cell-binding studies, along with in vitro and in vivo transduction assays, showed that the major ADK8 epitope is formed by an AAV variable region, VRVIII (amino acids 586 to 591 [AAV8 VP1 numbering]), which lies on the surface of the protrusions facing the 3-fold axis. This region plays a role in AAV2 and AAV8 cellular transduction. Coincidently, cell binding and trafficking assays indicate that ADK8 affects a postentry step required for successful virus trafficking to the nucleus, suggesting a probable mechanism of neutralization. This structure-directed strategy for characterizing the antigenic regions of AAVs can thus generate useful information to help re-engineer vectors that escape host neutralization and are hence more efficacious.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593150      PMCID: PMC3421660          DOI: 10.1128/JVI.00218-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  87 in total

1.  Multi-resolution contour-based fitting of macromolecular structures.

Authors:  Pablo Chacón; Willy Wriggers
Journal:  J Mol Biol       Date:  2002-03-29       Impact factor: 5.469

2.  A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Authors:  Stephanie Kronenberg; Bettina Böttcher; Claus W von der Lieth; Svenja Bleker; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

4.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

5.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.

Authors:  Lili Wang; Roberto Calcedo; Peter Bell; Jianping Lin; Rebecca L Grant; Don L Siegel; James M Wilson
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

6.  Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Authors:  Ciaran D Scallan; Haiyan Jiang; Tongyao Liu; Susannah Patarroyo-White; Jurg M Sommer; Shangzhen Zhou; Linda B Couto; Glenn F Pierce
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

7.  Subcellular compartmentalization of adeno-associated virus type 2 assembly.

Authors:  A Wistuba; A Kern; S Weger; D Grimm; J A Kleinschmidt
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  AAV's anatomy: roadmap for optimizing vectors for translational success.

Authors:  Angela M Mitchell; Sarah C Nicolson; Jayme K Warischalk; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2010-10       Impact factor: 4.391

Review 9.  Interactions of protein antigens with antibodies.

Authors:  D R Davies; G H Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle.

Authors:  Aravind Asokan; Julia C Conway; Jana L Phillips; Chengwen Li; Julia Hegge; Rebecca Sinnott; Swati Yadav; Nina DiPrimio; Hyun-Joo Nam; Mavis Agbandje-McKenna; Scott McPhee; Jon Wolff; R Jude Samulski
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

View more
  55 in total

Review 1.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

2.  Capsid antibodies to different adeno-associated virus serotypes bind common regions.

Authors:  Brittney L Gurda; Michael A DiMattia; Edward B Miller; Antonette Bennett; Robert McKenna; Wendy S Weichert; Christian D Nelson; Wei-jun Chen; Nicholas Muzyczka; Norman H Olson; Robert S Sinkovits; John A Chiorini; Sergei Zolotutkhin; Olga G Kozyreva; R Jude Samulski; Timothy S Baker; Colin R Parrish; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

3.  Structural insights into adeno-associated virus serotype 5.

Authors:  Lakshmanan Govindasamy; Michael A DiMattia; Brittney L Gurda; Sujata Halder; Robert McKenna; John A Chiorini; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

4.  Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2.

Authors:  Antonette Bennett; Annahita Keravala; Victoria Makal; Justin Kurian; Brahim Belbellaa; Rangoli Aeran; Yu-Shan Tseng; Duncan Sousa; John Spear; Mehdi Gasmi; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2019-12-16       Impact factor: 2.867

5.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

Review 6.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 7.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

8.  Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.

Authors:  Dwaipayan Sen; Rupali A Gadkari; Govindarajan Sudha; Nishanth Gabriel; Yesupatham Sathish Kumar; Ruchita Selot; Rekha Samuel; Sumathi Rajalingam; V Ramya; Sukesh C Nair; Narayanaswamy Srinivasan; Alok Srivastava; Giridhara R Jayandharan
Journal:  Hum Gene Ther Methods       Date:  2013-04       Impact factor: 2.396

9.  Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging.

Authors:  Lauren M Drouin; Bridget Lins; Maria Janssen; Antonette Bennett; Paul Chipman; Robert McKenna; Weijun Chen; Nicholas Muzyczka; Giovanni Cardone; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure.

Authors:  Weimin Wu; Zhaochun Chen; Naiqian Cheng; Norman R Watts; Stephen J Stahl; Patrizia Farci; Robert H Purcell; Paul T Wingfield; Alasdair C Steven
Journal:  J Struct Biol       Date:  2012-10-16       Impact factor: 2.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.